Your browser doesn't support javascript.
loading
Interpreting In Vitro Release Performance from Long-Acting Parenteral Nanosuspensions Using USP-4 Dissolution and Spectroscopic Techniques.
Rudd, Nathan D; Reibarkh, Mikhail; Fang, Rui; Mittal, Sachin; Walsh, Paul L; Brunskill, Andrew P J; Forrest, William P.
Afiliação
  • Rudd ND; Analytical Sciences, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
  • Reibarkh M; Analytical Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
  • Fang R; Sterile & Specialty Products, Merck & Co., Inc., Kenilworth, New Jersey 07033, United States.
  • Mittal S; Sterile & Specialty Products, Merck & Co., Inc., Kenilworth, New Jersey 07033, United States.
  • Walsh PL; Analytical Sciences, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
  • Brunskill APJ; Analytical Sciences, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
  • Forrest WP; Sterile & Specialty Products, Merck & Co., Inc., Kenilworth, New Jersey 07033, United States.
Mol Pharm ; 17(5): 1734-1747, 2020 05 04.
Article em En | MEDLINE | ID: mdl-32267708
ABSTRACT
Injectable sustained release dosage forms have emerged as desirable therapeutic routes for patients that require life-long treatments. The prevalence of drug molecules with low aqueous solubility and bioavailability has added momentum toward the development of suspension-based long-acting parenteral (LAP) formulations; the previously undesirable physicochemical properties of Biopharmaceutics Classification System (BCS) Class II/IV compounds are best suited for extended release applications. Effective in vitro release (IVR) testing of crystalline suspensions affirms product quality during early-stage development and provides connections with in vivo performance. However, before in vitro-in vivo correlations (IVIVCs) can be established, it is necessary to evaluate formulation attributes that directly affect IVR properties. In this work, a series of crystalline LAP nanosuspensions were formulated with different stabilizing polymers and applied to a continuous flow-through (USP-4) dissolution method. This technique confirmed the role of salt effects on the stability of polymer-coated nanoparticles through the detection of disparate active pharmaceutical ingredient (API) release profiles. The polymer stabilizers with extended hydrophilic chains exhibited elevated intrapolymer activity from the loss of hydrogen-bond cushioning in dissolution media with heightened ionic strength, confirmed through one-dimensional (1D) 1H NMR and two-dimensional nuclear Overhauser effect spectroscopy (2D NOESY) experiments. Thus, steric repulsion within the affected nanosuspensions was limited and release rates decreased. Additionally, the strength of interaction between hydrophobic polymer components and the API crystalline surface contributed to suspension dissolution properties, confirmed through solution- and solid-state spectroscopic analyses. This study provides a unique perspective on the dynamic interface between the crystalline drug and aqueous microenvironment during dissolution.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Solubilidade / Suspensões / Liberação Controlada de Fármacos Tipo de estudo: Risk_factors_studies Idioma: En Revista: Mol Pharm Assunto da revista: BIOLOGIA MOLECULAR / FARMACIA / FARMACOLOGIA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Solubilidade / Suspensões / Liberação Controlada de Fármacos Tipo de estudo: Risk_factors_studies Idioma: En Revista: Mol Pharm Assunto da revista: BIOLOGIA MOLECULAR / FARMACIA / FARMACOLOGIA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos